Serotonin-to-dopamine transporter ratios in Parkinson disease

Neurology

Volumn 86, Issue 12, 2016, Pages 1152-1158

  Roussakis, Andreas Antonios ^a   Politis, Marios ^b   Towey, David ^c   Piccini, Paola ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 4 (2 DIMETHYLAMINOMETHYLPHENYL SULFANYL) BENZONITRILE C 11; DOPAMINE TRANSPORTER; LEVODOPA; N W FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE DURATION; DRUG BINDING; FEMALE; HUMAN; IDIOPATHIC DISEASE; IN VIVO STUDY; LEVODOPA-INDUCED DYSKINESIA; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; DYSKINESIA; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING;

AGED; BIOMARKERS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84961579281     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002494     Document Type: Article

References (34)

1. Winkler C, Kirik D, Björklund A, Cenci MA. L-DOPAinduced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson?s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis. 2002; 10: 165-186.
2. Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Långström B. Levodopa-induced changes in synaptic dopamine in patients with Parkinson?s disease as measured by [11C]raclopride displacement and PET. Neurology. 1996; 46: 1430-1436.
3. de la Fuente-Fernández R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson?s disease: implications for dyskinesias. Brain. 2004; 127: 2747-2754.
4. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology. 2006; 67: 1612-1617.
5. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson?s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry. 1986; 49: 853-860.
6. Ng KY, Chase TN, Colburn RW, Kopin IJ. Dopainduced release of cerebral monoamines. Science. 1970; 170: 76-77.
7. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M. Role of serotonergic neurons in L-DOPAderived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport. 1999; 10: 631-634.
8. Maeda T, Nagata K, Yoshida Y, Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res. 2005; 1046: 230-233.
9. Kannari K, Shen H, Arai A, Tomiyama M, Baba M. Reuptake of L-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci Lett. 2006; 402: 62-65.
10. Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPAinduced dyskinesia in parkinsonian rats. Brain. 2007; 130: 1819-1833.
11. Rylander D, Parent M, O?Sullivan SS, et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol. 2010; 68: 619-628.
12. Bézard E, Tronci E, Pioli EY, et al. Study of the antidyskinetic effect of eltoprazine in animal models of levodopainduced dyskinesia. Mov Disord. 2013; 28: 1088-1096.
13. Politis M, Wu K, Loane C, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson?s disease patients. J Clin Invest. 2014; 124: 1340-1349.
14. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci. 1995; 15: 1714-1723.
15. Kish SJ, Furukawa Y, Chang LJ, et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?. Nucl Med Biol. 2005; 32: 123-128.
16. Piccini P. Dopamine transporter: basic aspects and neuroimaging. Mov Disord. 2003; 18(suppl 7): S3-S8.
17. Politis M, Wu K, Loane C, et al. Staging of serotonergic dysfunction in Parkinson?s disease: an in vivo 11C-DASB PET study. Neurobiol Dis. 2010; 40: 216-221.
18. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson?s disease: a clinicopathologic study. Neurology. 1992; 42: 1142-1146.
19. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997; 6: 279-287.
20. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996; 16: 834-840.
21. Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S. Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab. 2001; 21: 1342-1353.
22. Politis M, Oertel WH, Wu K, et al. Graft-induced dyskinesias in Parkinson?s disease: high striatal serotonin/dopamine transporter ratio. Mov Disord. 2011; 26: 1997-2003.
23. Piccini P, Brooks DJ, Björklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson?s patient. Nat Neurosci. 1999; 2: 1137-1140.
24. de la Fuente-Fernández R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson?s disease: PET evidence of increased dopamine turnover. Ann Neurol. 2001; 49: 298-303.
25. Sossi V, de la Fuente-Fernández R, Schulzer M, Adams J, Stoessl J. Age-related differences in levodopa dynamics in Parkinson?s: implications for motor complications. Brain. 2006; 129: 1050-1058.
26. Nevalainen N, Af Bjerkén S, Gerhardt GA, Strömberg I. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia. Neuroscience. 2014; 260: 73-86.
27. Conti MM, Ostock CY, Lindenbach D, et al. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology. 2014; 77: 1-8.
28. Muñoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPAinduced dyskinesia. Brain. 2008; 131: 3380-3394.
29. Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson?s disease: a dose-finding study. Brain. 2015; 138: 963-973.
30. Suwijn SR, Berendse HW, Verschuur CV, Winogrodzka A, de Bie RM, Booij J. SERT-To-DAT ratios in early Parkinson?s disease do not correlate with the development of dyskinesias. EJNMMI Res. 2013; 3: 44.
31. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson?s disease. J Neurol. 1999; 246: 1127-1133.
32. Wickremaratchi MM, Knipe MD, Sastry BS, et al. The motor phenotype of Parkinson?s disease in relation to age at onset. Mov Disord. 2011; 26: 457-463.
33. Olanow WC, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson?s disease. Mov Disord. 2013; 28: 1064-1071.
34. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson?s disease: a community-based study. Brain. 2000; 123: 2297-2305.